Aaron Rapoport, MD
Hematology · Baltimore, MDNPI 1356309280
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Gilead accounts for 74.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $116 and has fallen 52.0% since, to $56 in 2025.
Across 6 payments — averaging $49.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$220
- AbbVie$32
- Pharmacyclics LLC, An Abbvie Company$22
- Johnson & Johnson$21
Across 169 payments — averaging $13,086 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$941K
- Gilead$728K
- GSK$531K
- Adaptimmune LLC$10K
- National Marrow Donor Program$1K
What the payments were for
- Food & beverage$296100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 3 | $220 |
| AbbVie | 1 | $32 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
How this compares
$296 in reported general payments places this provider in the 60th percentile of 28 hematology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 32 | $324,052 |
| CalquenceAcalabrutinib Maleate | 15 | $218,979 |
| Lenalidomide | 12 | $155,614 |
| Imatinib Mesylate | 13 | $8,237 |
| Atovaquone | 19 | $6,796 |
| ValacyclovirValacyclovir Hcl | 81 | $4,076 |
| Acyclovir | 80 | $1,519 |
| Doxycycline Monohydrate | 12 | $810 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 67 | $448 |
| Pantoprazole Sodium | 16 | $249 |
| Prochlorperazine Maleate | 13 | $155 |
| Metoprolol Succinate | 13 | $125 |
| Gabapentin | 12 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $22 | $324,05232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 28 hematology providers in Maryland.
Other hematology in Baltimore
- Jerry SpivakBaltimore$98K
- Michael KallenBaltimore$53K
- Gloria GerberBaltimore$41K
- Robert BrodskyBaltimore$27K
- Djordje AtanackovicBaltimore$11K
- Michael ColeBaltimore$7K
- Alison MoliternoBaltimore$3K
- Max BrodskyBaltimore$305
- Jeffrey SeibelBaltimore$129
- Hector Mesa CorralesBaltimore$123
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.